Physician profile
Benson Onghai
NPI 1366499501
$3,096.97
in general payments reported to CMS, 2019-2025
23 companies · $200 in 2025
The $200 reported for 2025 was more than what a typical Physical Medicine & Rehabilitation provider received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $632 · 2020: $456 · 2021: $441 · 2022: $363 · 2023: $546 · 2024: $458 · 2025: $200.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,204.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,204.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $827.83 | 2019-2025 | Lokelma, Airsupra, Breztri |
| Regeneron Healthcare Solutions, INC. | $249.27 | 2021-2022 | |
| Acadia Pharmaceuticals INC | $215.44 | 2022-2024 | Nuplazid |
| Lilly USA, LLC | $202.70 | 2019-2024 | Zepbound |
| Novo Nordisk INC | $166.74 | 2019-2020 | |
| Si-Bone, INC. | $162.25 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $125.00 | 2023 | |
| Amgen INC. | $124.96 | 2020 | |
| Novartis Pharmaceuticals Corporation | $124.77 | 2020 | |
| Esperion Therapeutics, INC. | $124.59 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $122.43 | 2019 | |
| Urovant Sciences INC | $120.00 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $111.91 | 2023 | Nuedexta |
| Janssen Pharmaceuticals, INC | $91.55 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $60.64 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $46.11 | 2023-2024 | Inspire |
| Djo, LLC | $44.48 | 2025 | Cmf |
| Abbott Laboratories | $40.83 | 2021 | |
| Misonix INC | $40.30 | 2019 | |
| Ferring Pharmaceuticals INC. | $38.49 | 2021-2024 | Euflexxa |
| Teva Pharmaceuticals USA, INC. | $25.26 | 2025 | Austedo Xr |
| Smith+Nephew, INC. | $17.92 | 2020 | |
| Medtronic, INC. | $13.50 | 2025 | Catalyft Pl Expandable Interbody System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benson Onghai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.